Design Therapeutics, Inc. (DSGN)

3.6000 -0.0500 (-1.37%) As of 11:17AM EDT. Market open.

Design Therapeutics, Inc.

6005 Hidden Valley Road
Suite 110
Carlsbad, CA 92011
United States
858 293 4900
https://www.designtx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 58

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Pratik Shah Ph.D.	Co-Founder, President, CEO, Principal Financial Officer & Executive Chairperson	638.46k	N/A	1970
Dr. Sean Jeffries Ph.D.	Chief Operating Officer	572.21k	N/A	1980
Dr. Aseem Z. Ansari Ph.D.	Co-Founder & Scientific Advisor	N/A	N/A	N/A
Ms. Julie D. Burgess CPA	Chief Accounting Officer	N/A	N/A	N/A
Dr. Jae B. Kim FACC, M.D.	Chief Medical Officer	N/A	N/A	1970
Ms. Dawn Giangiulio	Controller	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

Corporate governance

Design Therapeutics, Inc.’s ISS governance QualityScore as of 1 April 2024 is 8. The pillar scores are Audit: 7; Board: 8; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.